Results 71 to 80 of about 5,269,973 (298)

Therapeutic Apheresis in Nigeria: Awareness, Knowledge Gaps, and Readiness for Service Expansion Among Healthcare Professionals

open access: yesTherapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Background Therapeutic apheresis (TA) is a specialized extracorporeal blood purification modality used in the management of complex hematologic, neurologic, and autoimmune diseases. Despite established global guidelines, its utilization in Nigeria remains largely undocumented.
Chimezie G. Okwuonu   +11 more
wiley   +1 more source

Enabling New Targets by Integrated Lead Discovery

open access: yes, 2015
Advances in biomedical science and technology are directing attention to drug targets that were previously deemed difficult or even "un-druggable". At Novartis, we have re-designed our approach to lead discovery to exploit these opportunities.
Schopfer, Ulrich, Cottens, Sylvain
core  

Discovery of a Novel Class of Orally Active Trypanocidal N-Myristoyltransferase Inhibitors [PDF]

open access: yes, 2011
N-Myristoyltransferase (NMT) represents a promising drug target for human African trypanosomiasis (HAT), which is caused by the parasitic protozoa Trypanosoma brucei.
Read, Kevin D.   +39 more
core   +1 more source

Gut microbiome and aging—A dynamic interplay of microbes, metabolites, and the immune system

open access: yesFEBS Letters, EarlyView.
Age‐dependent shifts in microbial communities engender shifts in microbial metabolite profiles. These in turn drive shifts in barrier surface permeability of the gut and brain and induce immune activation. When paired with preexisting age‐related chronic inflammation this increases the risk of neuroinflammation and neurodegenerative diseases.
Aaron Mehl, Eran Blacher
wiley   +1 more source

Perspectives on phenotypic screening−Screen Design and Assay Technology Special Interest Group

open access: yesSLAS Discovery
Here we offer perspectives on phenotypic screening based on a wide-ranging discussion entitled “Phenotypic screening, target ID, and multi-omics: enabling more disease relevance in early discovery?” at the Screen Design and Assay Technology Special ...
Chorom Pak   +5 more
doaj   +1 more source

Antidiabetic and cardiovascular beneficial effects of a liver-localized mitochondrial uncoupler

open access: yesNature Communications, 2019
Mitochondrial uncoupling is a treatment strategy for metabolic diseases that reduces the efficiency of mitochondrial oxidative phosphorylation and ATP generation.
Naohide Kanemoto   +12 more
doaj   +1 more source

E-selectin antagonists: fragment-based drug discovery and lead optimization by NMR and BIAcore [PDF]

open access: yes, 2012
The inflammatory response consists of a well-defined and regulated multi-step cascade leading to extravasation of leukocytes from the blood to sites of inflammation. The transmigration of leukocytes is initiated by their interaction with the endothelium,
Weckerle, Céline
core   +1 more source

The human gut microbiome across the life course

open access: yesFEBS Letters, EarlyView.
Despite significant individual variation and continuous change throughout life, the human gut microbiome follows some life stage‐specific trends. This article provides a brief overview of how gut microbiome composition shifts across different phases of life. Created in BioRender. Özkurt, E. (2026) https://BioRender.com/8q4nrnc.
Alise J. Ponsero   +4 more
wiley   +1 more source

Degradation mechanism of the von Willebrand factor A2 domain by nattokinase

open access: yesFEBS Letters, EarlyView.
Nattokinase, a natto‐derived protease, exhibits potent antithrombotic effects. This study demonstrates that nattokinase directly cleaves the von Willebrand factor (vWF) A2 domain in vitro. Unlike the native regulator ADAMTS13, nattokinase degrades folded vWF independently of shear stress.
Ryuichi Hyakumoto   +3 more
wiley   +1 more source

Why is Price Discovery in Credit Default Swap Markets News-Specific? [PDF]

open access: yes
: We analyse daily lead-lag patterns in US equity and credit default swap (CDS) returns. We first document that equity returns robustly lead CDS returns.
Marsch, I., Wagner, W.B.
core  

Home - About - Disclaimer - Privacy